http://www.bloomberg.com/apps/news?pid=20601103&sid=aA60zcLRsbKQ
By Shannon Pettypiece
Oct. 16 (Bloomberg) -- Merck & Co.’s Gardasil, a vaccine used to prevent cervical cancer in women, won U.S. regulatory approval for preventing genital warts in boys.
The U.S. Food and Drug Administration cleared the vaccine for use in males ages 9 to 26, Merck said today in a statement.
Gardasil protects against a sexually transmitted infection called human papillomavirus, or HPV, that can lead to cervical cancer in women and genital warts and cancer of the penis and anus in men. Gardasil, approved for females ages 9 to 26, is given mostly to school-age girls as a U.S.-recommended routine vaccination. Expanding the shot’s use could revive sales, which declined 5 percent last year, analysts have said.
READ ENTIRE ARTICLE HERE:
http://www.bloomberg.com/apps/news?pid=20601103&sid=aA60zcLRsbKQ
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment